Lipid Research Group

About us

Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and premature death worldwide. To a large extent, this is a consequence of the ageing population, as well as the increasing prevalence of obesity and type 2 diabetes in younger generations. High plasma HDL cholesterol levels are associated with a reduced risk of ASCVD. This benefit may be related to the multiple cardioprotective functions HDLs. We have recently shown that HDLs also have anti-diabetic properties.

The overall goal of the Lipid Research Group is to understand the mechanisms that underlie the development of ASCVD and the identification of novel therapeutic approaches for treating ASCVD and type 2 diabetes.

Current Projects

  • The role of HDLs in type 2 diabetes
  • Development of mimetic peptides as anti-atherisclerotic and anti-diabetic therapies
  • Identification of novel cardioprotective functions of HDL apolipoproteins
  • Regulation of ASCVD by miRNAs
  • Identification of novel biomarkers that predict cardiovascular risk

Research Opportunities

There are opportunities for Honours, PhD and ILP students: contact Prof Kerry-Anne Rye for details of specific projects.

Team

Collaborators

  • Dr Gary Ren, Lawrence Berkeley Laboratory, CA, USA.

HDLstructure and function

Interactions of HDLs and cholesteryl ester transfer protein

  • Dr Alan RemaleyNHLBI, Bethesda, MD, USA

Regulation of HDL function by mimetic peptides

  • Dr Anatol Kontush, INSERM Unit 551, Paris.

·             Role of phosphatidylserine in HDL function

  • A/Prof Veronique Angeli, National University of Singapore

·             ApoA-I and lymphatic biology

  • Dr Kasey Vickers, Vanderbilt University, TN, USA

·             miRNAs in health and disease

Resources & Tools

Fryirs, M.A., Barter, P.J., Appavaroo, M., Tuch, B.E., Tabet, F., Heather, A.K. and Rye, K.-A. Effects of High Density Lipoproteins on Pancreatic β-Cell Insulin SecretionArterioscler. Thromb. Vasc. Biol.2010 30:1642-1648

Tabet, F., Lambert, G, Cuesta Torres, L.F., Hou, L., Sotirchos, I., Touyz, R.M., Jenkins, A.J., Barter, P.J., and Rye, K.-A. Lipid-free apolipoprotein A-I and discoidal reconstituted HDL differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler. Thromb. Vasc. Biol.2011 31:1192-1200

Barter, P.J., Rye, K.-A., Tardif, J.-C., Waters, D.D., Boekholdt, S.M., Breazna, A., and Kastelein, J.J. Effect of Torcetrapib on glucose, insulin and HbA1c in subjects with diabetes in the ILLUMINATE trial. Circulation. 2011 124:555-562

Ong, K.L., Tso, A.W.K., Xu, A., Law, L.S.C., Li, M., Wat, N.M.S., Rye, K.-A., Lam, T.H., Cheung, B.M.Y., Lam, K.S.L.Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemiaafter a median of 5.4 years. Diabetologia. 2011 54:2552-2560

Barter, P.J., and Rye, K.-A. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Trends in Pharmacological Sciences. 2011 32:694-699

Wu, B.J., Chen, K., Barter, P.J. and Rye, K.-A. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation. 2012 125:150-158

Ong, K.L., Rye, K.-A., O’Connell, R., Jenkins, A.J., Brown, C., Sullivan, D.R.,

Barter, P.J. and Keech, A.C. on behalf of the FIELD study investigators. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2012 97:4701-4708 

Grants & Funding

Students

  • Sudichhya Shrestha – PhD
  • Zubair Ibrahim, PhD
  • Alex Dupuy, Honours
  • Sahapab Anuwatmatee, ILP
  • Thampi Rawther, ILP